Evidence map›Paper›PMID 37614155›Full record

ArticlePsychiatric services (Washington, D.C.)2024

Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.

Helen Newton, Chris Miller-Rosales, Maia Crawford, Arno Cai, Mary Brunette, Ellen Meara

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Helen NewtonDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Chris Miller-RosalesDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Maia CrawfordDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Arno CaiDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Mary BrunetteDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Ellen MearaDepartment of Family Medicine, University of North Carolina School of Medicine, Chapel Hill (Newton); Department of Health Care Policy, Harvard Medical School, Boston (Miller-Rosales); Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire (Crawford); Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston (Cai, Meara); Department of Psychiatry, Dartmouth Geisel School of Medicine, Hanover, New Hampshire (Brunette).
Dartmouth Institute for Health Policy and Clinical Practice · US

Funding

Health Policy Training Program: Promoting Outcomes, Quality, Equity and Diffusion of AdvancesT32MH019733 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Benjamin Le Cook, Haiden A Huskamp · 1993 to 2026
$7.0M
Stemming the Tide: The Role of Payment and Delivery System Reform in Combating the Opioid EpidemicR01DA049757 · NIDA · DARTMOUTH COLLEGE · PI LEWINSON, TERRI D, MEARA, ELLEN R. · 2020 to 2023
$2.6M
NIDA NIH HHS R01 DA049757NIMH NIH HHS T32 MH019733
6 · The paper itself

Abstract

objectiveThis report aimed to assess how accountable care organizations (ACOs) addressed ongoing opioid use disorder treatment needs over time.

methodsResponses from the 2018 (N=308 organizations) and 2022 (N=276) National Survey of Accountable Care Organizations (response rate=55% in both years) were used to examine changes in availability of medication for opioid use disorder (MOUD) among ACOs with Medicare and Medicaid contracts.

resultsThe percentage of respondents offering at least one MOUD grew from 39% in 2018 to 52% in 2022 (p<0.01). MOUDs were more likely to be available in 2022 among ACOs with (vs. without) in-network substance use treatment facilities (80% vs. 33%, p<0.001). The percentage of 2022 respondents who reported offering MOUD was similar in states with high versus low opioid overdose mortality rates.

conclusionsDespite growing availability of MOUD among ACOs, nearly half reported not offering any MOUD in 2022, and the availability of MOUD did not increase with treatment need.

Indexed as

Accountable Care OrganizationsBuprenorphineOpioid-Related DisordersAgedHumansMedicaidMedicareUnited StatesBuprenorphineAccountable care organizationsDrug abusePublic health

Identifiers

PMID37614155
PMCPMC10895446
OpenAlexW4386116530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.